SEC Tracker
Get the app

Marpai MRAI

Marpai FY 2021: revenue $14.2M; diluted EPS −$25.44

Form
10-K
Filed
Period
Importance
Notable
Document
10-K
Exhibit 4.68
Warrants or notes
Exhibit 10.14
Material contract
Exhibit 10.29
Material contract
Exhibit 10.30
Material contract

Key figures from this report

These are the numbers Marpai reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$14.2MNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Net income−$16.0MNo year-earlier figure tagged10-K income statement, on EDGAR
  3. Diluted EPS−$25.44No year-earlier figure tagged. Split-adjusted, as the tables show it; the filing reported −$1.5910-K income statement, on EDGAR
  4. Cash and cash equivalents$19.2MNo year-earlier figure tagged10-K balance sheet, on EDGAR
  5. Cash from operations−$10.8MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Marpai files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8090 and related industry codes: the same peer list as the financial tables.

  1. BioRestorative Therapies BRTX public float $11M, Jun 30, 2025
  2. Mangoceuticals MGRX public float $15M, Jun 30, 2025
  3. Elite Health Systems EHSI public float $24M, Jun 30, 2025
  4. Cryo Cell International CCEL public float $27M, May 31, 2025
  5. Pacific Health Care Organization PFHO public float $3M, Jun 30, 2025